| Title |
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, October 2018
|
| DOI | 10.1186/s40425-018-0420-0 |
| Pubmed ID | |
| Authors |
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers |
X Demographics
The data shown below were collected from the profiles of 44 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 21 | 48% |
| France | 3 | 7% |
| Spain | 2 | 5% |
| Singapore | 1 | 2% |
| Canada | 1 | 2% |
| Japan | 1 | 2% |
| United Kingdom | 1 | 2% |
| Switzerland | 1 | 2% |
| Unknown | 13 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 36% |
| Practitioners (doctors, other healthcare professionals) | 15 | 34% |
| Scientists | 10 | 23% |
| Science communicators (journalists, bloggers, editors) | 3 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 117 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 15 | 13% |
| Student > Ph. D. Student | 15 | 13% |
| Researcher | 15 | 13% |
| Student > Bachelor | 8 | 7% |
| Student > Postgraduate | 8 | 7% |
| Other | 19 | 16% |
| Unknown | 37 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 32% |
| Biochemistry, Genetics and Molecular Biology | 9 | 8% |
| Agricultural and Biological Sciences | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Immunology and Microbiology | 5 | 4% |
| Other | 10 | 9% |
| Unknown | 41 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2023.
All research outputs
#1,235,582
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#293
of 3,424 outputs
Outputs of similar age
#26,723
of 361,526 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#5
of 54 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.